

# Tanya Siddiqi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/140058/publications.pdf>

Version: 2024-02-01

136  
papers

12,651  
citations

94381

37  
h-index

25770

108  
g-index

136  
all docs

136  
docs citations

136  
times ranked

10938  
citing authors

#	ARTICLE	IF	CITATIONS
1	Axicabtagene Ciloleucl CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	13.9	3,865
2	Long-term safety and activity of axicabtagene ciloleucl in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 31-42.	5.1	1,467
3	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	13.9	1,261
4	Lisocabtagene maraleucl for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. <i>Lancet</i> , The, 2020, 396, 839-852.	6.3	1,224
5	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. <i>Molecular Therapy</i> , 2017, 25, 285-295.	3.7	498
6	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 1409-1418.	5.1	290
7	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. <i>Blood</i> , 2020, 136, 2038-2050.	0.6	281
8	Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. <i>Blood</i> , 2014, 123, 3095-3100.	0.6	280
9	Phase 1 studies of central memory-derived CD19 CAR T cell therapy following autologous HSCT in patients with B-cell NHL. <i>Blood</i> , 2016, 127, 2980-2990.	0.6	264
10	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. <i>Leukemia</i> , 2018, 32, 1768-1777.	3.3	184
11	NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1289-1303.	2.3	168
12	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 24-31.	0.8	152
13	Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2136-2140.	2.0	131
14	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3853-3865.	0.8	115
15	Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1079-1095.	2.3	100
16	Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucl (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas. <i>Blood</i> , 2019, 134, 241-241.	0.6	89
17	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. <i>Blood</i> , 2022, 139, 3278-3289.	0.6	83
18	Venous Thromboembolic Disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1402-1429.	2.3	80

#	ARTICLE	IF	CITATIONS
19	Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). <i>Blood</i> , 2019, 134, 764-764.	0.6	77
20	Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 1811-1820.	0.6	75
21	A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, 357-362.	1.7	66
22	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. <i>Blood</i> , 2022, 139, 1794-1806.	0.6	66
23	Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. <i>Lancet Haematology</i> , 2019, 6, e100-e109.	2.2	65
24	CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. <i>Blood Advances</i> , 2021, 5, 4059-4063.	2.5	62
25	Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 581.e1-581.e8.	0.6	61
26	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. <i>Blood Advances</i> , 2020, 4, 6009-6018.	2.5	57
27	Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1864-1868.	2.0	56
28	Venetoclax in Previously Treated Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 63-71.	0.8	53
29	NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 12-20.	2.3	52
30	Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001. <i>Blood</i> , 2020, 136, 10-11.	0.6	52
31	Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL). <i>Blood</i> , 2021, 138, 1764-1764.	0.6	48
32	Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. <i>Blood</i> , 2010, 115, 2901-2909.	0.6	46
33	Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. <i>Leukemia and Lymphoma</i> , 2017, 58, 1607-1616.	0.6	46
34	Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1181-1201.	2.3	43
35	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4149-4155.	2.5	42
36	A Case of HIV-Negative Primary Effusion Lymphoma Treated with Bortezomib, Pegylated Liposomal Doxorubicin, and Rituximab. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 300-304.	1.4	41

#	ARTICLE	IF	CITATIONS
37	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , 2019, 134, 35-35.	0.6	40
38	Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2020, 136, 39-40.	0.6	40
39	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 185-217.	2.3	40
40	Impact of Pretransplantation 18F-fluorodeoxy Glucoseâ€“Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39
41	Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study. <i>Blood</i> , 2020, 136, 37-39.	0.6	37
42	Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 978-986.	1.3	36
43	Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL). <i>Blood</i> , 2021, 138, 2840-2840.	0.6	34
44	Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATEâ„¢-17 Trial. <i>Blood</i> , 2014, 124, 327-327.	0.6	33
45	NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 622-634.	2.3	33
46	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , 2020, 136, 16-17.	0.6	32
47	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 514-520.	2.0	31
48	Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1. <i>Blood</i> , 2016, 128, LBA-6-LBA-6.	0.6	30
49	Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients. <i>Blood</i> , 2020, 136, 40-41.	0.6	26
50	A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1. <i>Blood</i> , 2016, 128, 998-998.	0.6	26
51	Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 4192-4192.	0.6	25
52	Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1414-1427.	2.3	24
53	The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. <i>Cancer Immunology Research</i> , 2021, 9, 75-88.	1.6	24
54	Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib. <i>Blood</i> , 2019, 134, 503-503.	0.6	24

#	ARTICLE	IF	CITATIONS
55	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. <i>Clinical Cancer Research</i> , 2021, 27, 4814-4824.	3.2	23
56	Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2020, 61, 309-317.	0.6	22
57	Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2888-2888.	0.6	22
58	Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1861-1869.	2.0	19
59	Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. <i>Blood Advances</i> , 2021, 5, 1695-1705.	2.5	18
60	Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. <i>Molecular Cell</i> , 2021, 81, 2094-2111.e9.	4.5	17
61	Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib. <i>Blood</i> , 2018, 132, 300-300.	0.6	17
62	Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7501-7501.	0.8	16
63	Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL. <i>Blood</i> , 2012, 120, 3699-3699.	0.6	16
64	Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 140, 2697-2708.	0.6	15
65	ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7521-7521.	0.8	14
66	2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma. <i>Blood</i> , 2018, 132, 2967-2967.	0.6	13
67	TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7501-7501.	0.8	13
68	ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8007-8007.	0.8	13
69	Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 79.	0.4	12
70	Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2018, 11, 87.	6.9	12
71	A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 738-747.	1.2	12
72	Long-term follow-up of the PI3K inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7512-7512.	0.8	12

#	ARTICLE	IF	CITATIONS
73	Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.. Journal of Clinical Oncology, 2018, 36, 3039-3039.	0.8	12
74	Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2021, 39, 7556-7556.	0.8	11
75	Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001.. Journal of Clinical Oncology, 2019, 37, 7515-7515.	0.8	11
76	CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma. Blood, 2019, 134, 4075-4075.	0.6	10
77	Targeted Therapies in CLL: Monotherapy Versus Combination Approaches. Current Hematologic Malignancy Reports, 2018, 13, 525-533.	1.2	9
78	A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.. Blood, 2012, 120, 2746-2746.	0.6	9
79	Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. Blood, 2014, 124, 501-501.	0.6	9
80	Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). Blood, 2015, 126, 3991-3991.	0.6	9
81	Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. Blood, 2015, 126, 519-519.	0.6	9
82	Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction. Blood, 2021, 138, 530-530.	0.6	9
83	Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. Blood Advances, 2022, 6, 4098-4106.	2.5	9
84	Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies. JAMA Network Open, 2020, 3, e204787.	2.8	8
85	A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma. Blood, 2019, 134, 4095-4095.	0.6	8
86	Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel). Blood, 2020, 136, 40-42.	0.6	8
87	Does antithymocyte globulin have a place in reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation?. Hematology American Society of Hematology Education Program, 2012, 2012, 246-50.	0.9	8
88	Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia and Lymphoma, 2021, 62, 3278-3282.	0.6	7
89	Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e667-e672.	0.2	6
90	Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results. Blood, 2015, 126, 1538-1538.	0.6	6

#	ARTICLE	IF	CITATIONS
91	Sarcopenia Is a Clinically Relevant and Independent Predictor of Health Outcomes after Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. <i>Blood</i> , 2021, 138, 2502-2502.	0.6	6
92	Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7571-7571.	0.8	6
93	Burkitt leukemia limited to the bone marrow has a better prognosis than Burkitt lymphoma with bone marrow involvement in adults. <i>Leukemia and Lymphoma</i> , 2016, 57, 866-871.	0.6	5
94	A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. <i>Investigational New Drugs</i> , 2021, 39, 1099-1105.	1.2	5
95	Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7552-7552.	0.8	5
96	Estimation of the Resource Utilization and Costs of Cytokine Release Syndrome Observed in the Transcend-NHL Clinical Trial: A Micro-Costing Study. <i>Blood</i> , 2018, 132, 319-319.	0.6	5
97	Cirtumzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study. <i>Blood</i> , 2020, 136, 45-46.	0.6	5
98	Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study. <i>Blood</i> , 2014, 124, 629-629.	0.6	5
99	Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene maraleucel (Liso-cel); Tj ETQq1 1 0.784304rgBT /Overlock		
100	Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3k $\hat{I}$ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 801-801.	0.6	4
101	Updated results of the ASPEN trial from a cohort of patients with <i>MYD88</i> wild-type ( <i>MYD88</i> <sup>WT</sup> ) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2020, 38, e20056-e20056.	0.8	4
102	Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7519-7519.	0.8	4
103	Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT. <i>Blood</i> , 2013, 122, 3374-3374.	0.6	3
104	Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 830-830.	0.6	3
105	ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3102-TPS3102.	0.8	3
106	A Phase I Trial of PI3K $\hat{I}$ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL). <i>Blood</i> , 2021, 138, 3558-3558.	0.6	3
107	The Cerebroventricular Environment Reprograms Locally Infused CAR T Cells for Superior Activity Against Both CNS and Systemic B Cell Lymphoma. <i>Blood</i> , 2018, 132, 965-965.	0.6	2
108	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Na $\hat{I}$ ve CLL/SLL (RESONATE-2TM). <i>Blood</i> , 2015, 126, 495-495.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 930-930.	0.6	2
110	Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7559-7559.	0.8	2
111	Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2015, 126, 2730-2730.	0.6	2
112	Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience. <i>Blood</i> , 2020, 136, 40-41.	0.6	2
113	Phase 1/2 study of zilovetamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7520-7520.	0.8	2
114	Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. <i>Blood</i> , 2018, 132, 4197-4197.	0.6	1
115	Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma. <i>Blood</i> , 2013, 122, 4398-4398.	0.6	1
116	Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies. <i>Blood</i> , 2014, 124, 4483-4483.	0.6	1
117	Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States. <i>Blood</i> , 2018, 132, 4414-4414.	0.6	1
118	Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL. <i>Blood</i> , 2019, 134, 1755-1755.	0.6	1
119	Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2021, 138, 3534-3534.	0.6	1
120	MGA deletion Leads to Richter's Transformation Via NME1. <i>Blood</i> , 2021, 138, 252-252.	0.6	1
121	Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1407-1407.	0.6	1
122	Chronic Lymphocytic Leukemia (CLL): Biology and Therapy. <i>Cancer Treatment and Research</i> , 2021, 181, 133-149.	0.2	0
123	A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. <i>Blood</i> , 2012, 120, 3698-3698.	0.6	0
124	Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies. <i>Blood</i> , 2015, 126, 2731-2731.	0.6	0
125	Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 1961-1961.	0.6	0
126	Small B-cell lymphocytic lymphoma and chronic lymphocytic leukemia. , 2017, , 47-73.		0



#	ARTICLE	IF	CITATIONS
127	Lymphoplasmacytic lymphoma in the era of next generation sequencing. , 2017, , 97-109.		0
128	Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).. Journal of Clinical Oncology, 2020, 38, e20046-e20046.	0.8	0
129	Pharmacologic Inhibition of SUMO-Activating Enzyme Potentiates Interferon Response and T Cell-Mediated Anti-Tumor Immunity in Chronic Lymphocytic Leukemia (CLL) and Lymphoma Models. Blood, 2021, 138, 3719-3719.	0.6	0
130	Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion. Blood, 2021, 138, 4098-4098.	0.6	0
131	Nedd8-Activating Enzyme Inhibition Enhances Anti-Tumor Immunity and PD1 Blockade in <i>In Vivo</i> lymphoma Models. Blood, 2021, 138, 2414-2414.	0.6	0
132	Fixed Duration Combination Therapy with Ibrutinib (ibr) and Venetoclax (ven) Leads to Deep Responses in Relapsed/Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Study. Blood, 2021, 138, 3754-3754.	0.6	0
133	Integrative Transcriptome and Quantitative Proteome Analyses Identify METTL3 As a Key Regulator for Aberrant RNA Processing in Chronic Lymphocytic Leukemia. Blood, 2020, 136, 12-12.	0.6	0
134	Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy. Blood, 2020, 136, 22-23.	0.6	0
135	Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies. Current Hematologic Malignancy Reports, 2022, 17, 39-45.	1.2	0
136	Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leukemia and Lymphoma, 2022, 63, 1580-1588.	0.6	0